Ribociclib

The EC approved Novartis' Kisqali for HR+/HER2- early breast cancer, reducing recurrence risk by 25.1%.

Novartis receives EC approval for Kisqali (ribociclib) to treat early breast cancer at high risk of recurrence. Kisqali, a CDK inhibitor, is now approved in combination with an aromatase inhibitor for HR+/HER2- EBC patients. The approval is based on the Phase 3 NATALEE trial, showing a 25.1% reduction in disease recurrence risk with Kisqali plus endocrine therapy compared to endocrine therapy alone.

EC approves Kisqali® (ribociclib) plus AI for HR+/HER2- early breast cancer, based on Phase III NATALEE trial showing 25.1% reduction in recurrence risk. Approval extends eligibility to more patients, addressing high risk of recurrence despite endocrine therapy.

The European Commission approved Novartis' Kisqali, in combination with an aromatase inhibitor, for the adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative breast cancer. This decision is based on the Phase III NATALEE trial results, showing a 25.1% decrease in disease recurrence risk. The approval follows the US FDA's recent approval for the same indication.

Novartis’ Kisqali approved by EC to reduce early breast cancer recurrence risk in HR-positive, HER2-negative patients, based on NATALEE trial results showing 25.1% reduction in recurrence risk with Kisqali plus endocrine therapy.

EC approves Kisqali (ribociclib) plus AI for HR+/HER2- EBC at high risk of recurrence, based on NATALEE trial results showing 25.1% reduction in disease recurrence risk with Kisqali plus ET vs. ET alone, consistent across subgroups.

Novartis announces EC approval of Kisqali for early breast cancer, based on NATALEE trial results showing 25.1% reduction in recurrence risk. The approval addresses a key unmet need for patients at high risk of cancer return.

Novartis to present over 65 abstracts at ASH and SABCS, highlighting commitment to cancer and blood disorder treatments, with an art exhibit at SABCS featuring personal breast cancer stories.

Novartis presents over 65 abstracts at ASH and SABCS, highlighting new data on Scemblix, Kisqali, and other treatments, emphasizing commitment to cancer and blood disorder patients. The company also showcases personal breast cancer stories at SABCS, aiming to uplift and unite the community.

Novartis to present over 65 abstracts at ASH and SABCS, including 96-week Scemblix results and Kisqali 4-year analysis. Data highlights commitment to cancer and blood disorder treatments.